Boric acid as a protector against paclitaxel genotoxicity

• Autorzy: Turkez H. , Tatar A. , Hacimuftuoglu A. , Ozdemir E.
• Języki publikacji: EN

Abstrakty

EN

 Paclitaxel (PAC) is an anticancer drug used for treatments of breast, ovarian and lung cancers. However, little data is; available in the literature on its potential genotoxicity on healthy human cells. On the other hand, boron deficiency and supplementation exert important biological effects in human and animal tissues. The biological effects of dietary boron are defined, but its interaction with PAC is not known for therapeutic uses. The aim of the present study was to determine whether boric acid (BA) confer a protection against PAC genotoxicity. After the application of PAC (10 or 20 μg/l) and BA (2.5 or 5 mg/l), the genotoxic effects were assessed by sister chromatid exchange (SCE) and micronucleus (MN) tests in human blood cultures. We also analyzed nuclear division index (NDI) in peripheral lymphocytes. Our results showed that PAC significantly (P < 0.05) increased the frequencies of SCEs and the formations of MNs in peripheral lymphocytes as compared to controls. PAC decreased the nuclear division index in lymphocyte cultures. Boric acid did not show cytotoxic or genotoxic effects at the concentrations tested. Furthermore, the PAC-induced increases in the genotoxicity and cytotoxicity indices were diminished by the addition of BA. The present study suggests for the first time that BA can prevent the genotoxicity of PAC on human lymphocytes.

Słowa kluczowe

EN

boric acid; paclitaxel; sister chromatid exchange; micronucleus; nuclear division index; genotoxicity; anticancer drug; human cell; human lymphocyte

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2010
• Tom: 57
• Numer: 1
• Opis fizyczny: p.95-97,fig.,ref.

Twórcy

autor

Turkez H.

• Ataturk University, Erzurum, Turkey

autor

Tatar A.

autor

Hacimuftuoglu A.

autor

Ozdemir E.

Bibliografia

• Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20: 4995-5004. 
• Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96: 636-645. 
• Chentanez V, Thanomsridejchai N, Duangmardphon N, Agthong S, Kaewsema A, Huanmanop T, Maneesri S (2009) Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai 92: 50-57. 
• Cunha KS, Reguly ML, Graf U, de Andrade HH (2001) Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 16: 79-84. 
• Della Torre P, Imondi AR, Bernardi C, Podesta A, Moneta D, Riflettuto M, Mazue G (1999) Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Cancer Chemother Pharmacol 44: 138-142. 
• Digue L, Orsiere T, De Meo M, Mattei MG, Depetris D, Duffaud F, Favre R, Botta A (1999) Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. Environ Mol Mutagen 34: 269-278. 
• Digue L, Orsiere T, Baciuchka-Palmaro M, Duffaud F, Pompili J, Favre R, Botta A (2002) Interest of studying the in vitro genotoxicity of an antineoplastic drug on healthy human cells: paclitaxel example. Bull Cancer 89: 887-892. 
• Ellinger-Ziegelbauer H, Fostel JM, Aruga C, Bauer D, Boitier E, Deng S, Dickinson D, Le Fevre AC, Fornace AJ Jr, Grenet O, Gu Y, Hoflack JC, Shiiyama M, Smith R, Snyder RD, Spire C, Tanaka G, Aubrecht J (2009) Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol Sci 110: 341-352. 
• Evans HJ, O'Riordan ML (1975) Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat Res 31: 135-148. 
• Fenech M (1993) The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res 285: 35-44. 
• Geyikoglu F, Turkez H (2008) Boron compounds reduce vanadium tetraoxide genotoxicity in human lymphocytes. Environ Toxicol Pharmacol 26: 342-347.
• Hunt CD, Idso JP (1999) Dietary boron as a physiological regulator of the normal inflammatory response: a review and current research progress. J Trace Elem Exp Med 12: 221-233.
• Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu G, Manavoglu O (2003) Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol 20: 237-245. 
• Konopacka M, Rogolinski J (2004) Thiamine prevents X-ray induction of genetic changes in human lymphocytes in vitro. Acta Biochim Pol 51: 839-843.  
• Lachkar S, Bota S, Nouvet G, Thiberville L (2006) Acute encephalopathy after infusion of paclitaxel. Rev Mal Respir 23: 73-77. 
• Lee M, Kwon J, Chung MK (2003) Enhanced prediction of potential rodent carcinogenicity by utilizing comet assay and apoptotic assay in combination. Mutat Res 541: 9-19. 
• Moos PJ, Fitzpatrick FA (1998) Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ 9: 687-697. 
• Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G (2004) Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10: 461-467. 
• Pawa S, Ali S (2006) Boron ameliorates fulminant hepatic failure by counteracting the changes associated with the oxidative stress. Chem Biol Interact 160: 89-98. 
• Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G (2003) Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res 9: 5756-5767. 
• Preisler VK, Wück D, Stopper H (1999) Combination of paclitaxel and radiation: genotoxicity in vitro in four mammalian cell lines. Cancer Lett 145: 29-33. 
• Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460. 
• Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T (2005) The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. Mutat Res 583: 105-119. 
• Rooney DE, Czepulkowski BH (1986) Human Cytogenetics: A Practical Approach. IRL Press Ltd., Oxford.
• Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374. 
• Turkez H (2008) Effects of boric acid and borax on titanium dioxide genotoxicity. J Appl Toxicol 28: 658-664. 
• Türkez H, Geyikoğlu F, Tatar A, Keleş S, Ozkan A (2007) Effects of some boron compounds on peripheral human blood. Z Naturforsch C 62: 889-896. 
• Von Hoff DD (1997) The taxoids: same roots, different drugs. Semin Oncol 24: (Suppl 13) 3-10. 
• Wang YF, Chen CY, Chung SF, Chiou YH, Lo HR (2004) Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells. Cancer Chemother Pharmacol 54: 322-330. 
• Wu DQ, Wu Y (1995) Micronucleus and sister chromatid exchange frequency in endemic fluorosis. Fluoride 28: 125-127.